OB-24
Based on 2 publication(s) in Google Scholar
OB-24 is a selective small-molecule HO-1 inhibitor (IC50 = 1.9 μM for HO-1 and IC50 for HO-2 >100 μM). OB-24 possesses anti-tumor and anti-metastatic properties. OB-24 can be studies in research such as prostate cancer, melanoma, ovarian carcinoma and lung metastasis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.21%
- No. CAS: 939825-12-4
- Fòrmula: C15H18BrClN2O2
- Peso molecular:373.67
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) OB-24
More
Actividad biológica
|
HO-1 1.9 μM (IC50) |
HO-2 >100 μM (IC50) |
OB-24 (10 μM, 24-48 h) results in around 20% growth inhibition and 62% HO-1 inhibition in PC3M cells[1].
OB-24 (6.5 μM) reduces cell proliferation by approximately 10%, HO-1 activity by 59%, protein carbonylation by 40%, and intracellular ROS by 43% in HO-1 overexpressing rat glioma C6 cells[1].
OB-24 (10 μM, 96 h) induces around 86% protein carbonylation inhibition, and 25% intracellular ROS inhibition in PC3M cells[1].
OB-24 (5-10 μM, 10 min) reduces activation of the MAPK ERK and p38 kinases but no clear inhibition is seen on JNK or AKT phosphorylation in PC3M cells and results in similar inhibition in LNCaP and DU145 cells[1].
OB-24 has selectivity to HO-1 (IC50 = 1.9 μM against HO-1 in rat spleen) whereas the IC50 against HO-2 in rat brain is >100 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
OB-24 (10-30 mg/kg, i.v., on days 1, 3, and 5 per cycle for 4 cycle) results in approximately 50% tumor growth reduction and lymph node and lung metastases with 30 mg/kg in PC3M Scid male mice bearing palpable advanced prostate cancer[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:PC3M Scid male mice bearing palpable PCA[1]
-
Dosage:10-30 mg/kg, on days 1, 3, and 5 per cycle for 4 cycle
-
Administration:Intravenous injection (i.v.)
-
Result:Resulted in approximately 50% tumor growth reduction and lymph node and lung metastases with 30 mg/kg dosage.
Had less effect with 10 mg/kg dosage.
Exceeded 90% inhibitory effects when combined with Taxol (10 mg/kg).
Chemical Information
-
No. CAS 939825-12-4
-
Appearance Solid
-
Peso molecular 373.67
-
Fòrmula C15H18BrClN2O2
-
Color Off-white to light yellow
-
SMILES
BrC1=CC=C(CCC2(CN3C=CN=C3)OCCO2)C=C1.Cl
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Chem Biol Interact
Oridonin exposure induces testicular impairment through regulating ferroptosis via HIF-1α/HO-1 activation and STUB1-driven GPX4 ubiquitination-dependent degradation. [Abstract]2026 Jan 5:423:111838. PMID: 41265811 -
bioRxiv
2024 Jun 28:2024.06.24.600383. PMID: 38979166
Solvente y solubilidad
DMSO : 100 mg/mL (267.62 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (6.69 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.69 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Alaoui-Jamali MA, et al. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009;69(20):8017-8024. [Content Brief]
[3]. Roman, G., et al., (2007). Heme oxygenase inhibition by 2-oxy-substituted 1-(1H-imidazol-1-yl)-4-phenylbutanes: effect of halogen substitution in the phenyl ring. Bioorganic & medicinal chemistry, 15(9), 3225–3234. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6762 mL | 13.3808 mL | 26.7616 mL | 66.9040 mL |
| 5 mM | 0.5352 mL | 2.6762 mL | 5.3523 mL | 13.3808 mL | |
| 10 mM | 0.2676 mL | 1.3381 mL | 2.6762 mL | 6.6904 mL | |
| 15 mM | 0.1784 mL | 0.8921 mL | 1.7841 mL | 4.4603 mL | |
| 20 mM | 0.1338 mL | 0.6690 mL | 1.3381 mL | 3.3452 mL | |
| 25 mM | 0.1070 mL | 0.5352 mL | 1.0705 mL | 2.6762 mL | |
| 30 mM | 0.0892 mL | 0.4460 mL | 0.8921 mL | 2.2301 mL | |
| 40 mM | 0.0669 mL | 0.3345 mL | 0.6690 mL | 1.6726 mL | |
| 50 mM | 0.0535 mL | 0.2676 mL | 0.5352 mL | 1.3381 mL | |
| 60 mM | 0.0446 mL | 0.2230 mL | 0.4460 mL | 1.1151 mL | |
| 80 mM | 0.0335 mL | 0.1673 mL | 0.3345 mL | 0.8363 mL | |
| 100 mM | 0.0268 mL | 0.1338 mL | 0.2676 mL | 0.6690 mL |
OB-24 Related Classifications
HY-118487 Related Classifications
Powered by Bioz